Oncologie médicale

Uzm. Dr. Barış Gezici

Praticien et chercheur İzmir Şehir Hastanesi İzmir
Ouvrir la page de l’établissement
Suggérer une correction

Est-ce votre profil ? Revendiquez-le et vérifiez vos informations.

Revendiquer le profil

Confiance

D’où viennent ces informations ?

La source est indiquée à côté de chaque information. Si vous constatez une erreur, vous pouvez suggérer une correction.

  • SpécialitéOncologie médicalesaglik.gov.trD’après la source
  • Établissementİzmir Şehir Hastanesisaglik.gov.trD’après la source
  • Publications10 publicationsOpenAlex, Europe PMCD’après la source
  • ORCID0000-0003-1151-6523ORCIDD’après la source
  • Dernière synchronisation5 novembre 2026 09:07https://izmirsehir.saglik.gov.tr/TR-1046789/doktorlarimiz.html#baris-gezicisaglik.gov.tr

Travaux scientifiques

Publications

10 publications

  1. Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab

    Immunotherapy, 2026

    DOI 10.1080/1750743x.2026.2662201 PMID 42011533 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  2. Successful rapid desensitization with 5-fluorouracil in a patient with metastatic sigmoid colon cancer: A case report

    Journal of Oncology Pharmacy Practice, 2026

    DOI 10.1177/10781552261478571 PMID 42585552 Source : OpenAlex

  3. Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70213 PMID 41147655 3 citations (Europe PMC) Source : OpenAlex

  4. Prevalence of Insomnia and Associated Factors in Female Patients Undergoing Chemotherapy

    Nature and science of sleep, 2025

    DOI 10.2147/nss.s554960 PMID 41084526 1 citation (Europe PMC) Texte intégral en libre accèsSource : Europe PMC

  5. CT-230 Evaluation of BK Polyomavirus Infection Frequency and Risk Factors Following Allogeneic Stem Cell Transplantation (allo-SCT): A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)01500-8 Source : OpenAlex

  6. POSTER: CT-232 Evaluation of the Effects of Cytomegalovirus and BK Polyomavirus Infections on Overall Survival Following Allogeneic Stem Cell Transplantation: A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)00889-3 Source : OpenAlex

  7. CT-232 Evaluation of the Effects of Cytomegalovirus and BK Polyomavirus Infections on Overall Survival Following Allogeneic Stem Cell Transplantation: A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)01501-x Source : OpenAlex

  8. POSTER: CT-127 Evaluation of Cytomegalovirus Infection/Disease Frequency and Risk Factors Following Allogeneic Stem Cell Transplantation: A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)00914-x Source : OpenAlex

  9. CT-127 Evaluation of Cytomegalovirus Infection/Disease Frequency and Risk Factors Following Allogeneic Stem Cell Transplantation: A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)01488-x Texte intégral en libre accèsSource : OpenAlex

  10. POSTER: CT-230 Evaluation of BK Polyomavirus Infection Frequency and Risk Factors Following Allogeneic Stem Cell Transplantation (allo-SCT): A Single Center Experience

    Clinical Lymphoma Myeloma & Leukemia, 2023

    DOI 10.1016/s2152-2650(23)00888-1 Source : OpenAlex